Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 103
Filter
1.
Int J Mol Sci ; 25(9)2024 Apr 30.
Article in English | MEDLINE | ID: mdl-38732160

ABSTRACT

Despite the end of the pandemic, coronavirus disease 2019 (COVID-19) remains a major public health concern. The first waves of the virus led to a better understanding of its pathogenesis, highlighting the fact that there is a specific pulmonary vascular disorder. Indeed, COVID-19 may predispose patients to thrombotic disease in both venous and arterial circulation, and many cases of severe acute pulmonary embolism have been reported. The demonstrated presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within the endothelial cells suggests that direct viral effects, in addition to indirect effects of perivascular inflammation and coagulopathy, may contribute to pulmonary vasculopathy in COVID-19. In this review, we discuss the pathological mechanisms leading to pulmonary vascular damage during acute infection, which appear to be mainly related to thromboembolic events, an impaired coagulation cascade, micro- and macrovascular thrombosis, endotheliitis and hypoxic pulmonary vasoconstriction. As many patients develop post-COVID symptoms, including dyspnea, we also discuss the hypothesis of pulmonary vascular damage and pulmonary hypertension as a sequela of the infection, which may be involved in the pathophysiology of long COVID.


Subject(s)
COVID-19 , SARS-CoV-2 , Humans , COVID-19/complications , COVID-19/virology , COVID-19/pathology , SARS-CoV-2/pathogenicity , Lung/blood supply , Lung/pathology , Lung/virology , Pulmonary Embolism/virology , Pulmonary Embolism/etiology , Hypertension, Pulmonary/etiology , Hypertension, Pulmonary/physiopathology , Hypertension, Pulmonary/virology , Hypertension, Pulmonary/pathology , Post-Acute COVID-19 Syndrome , Thrombosis/virology , Thrombosis/etiology , Thrombosis/pathology
3.
Pulm Pharmacol Ther ; 71: 102082, 2021 12.
Article in English | MEDLINE | ID: mdl-34601121

ABSTRACT

COVID-19 pandemic has changed the world dramatically since was first reported in Wuhan city, China [1]. Not only as a respiratory illness that could lead to fatal respiratory failure, but also some evidences suggest that it can propagate as a chronic disease associated with a variety of persistent post COVID-19 pathologies that affect patients' life [2,3]. Pulmonary hypertension (PH) is one of the challenging diseases that may develop as a consequence of SARS-COV-2 infection in some COVID-19 survivors [4,5]. The vasopressor, proliferative, proinflammatory, and prothrombotic actions of endothelin [6] may be encountered in the COVID-19-induced PH pathology. And so, endothelin blockers may have an important role to restrict the development of serious PH outcomes with special precautions considering patients with significant hypoxemia.


Subject(s)
COVID-19 , Endothelins , Hypertension, Pulmonary , COVID-19/complications , Humans , Hypertension, Pulmonary/virology , Pandemics
4.
JCI Insight ; 6(15)2021 08 09.
Article in English | MEDLINE | ID: mdl-34185707

ABSTRACT

We previously reported heightened expression of the human endogenous retroviral protein HERV-K deoxyuridine triphosphate nucleotidohydrolase (dUTPase) in circulating monocytes and pulmonary arterial (PA) adventitial macrophages of patients with PA hypertension (PAH). Furthermore, recombinant HERV-K dUTPase increased IL-6 in PA endothelial cells (PAECs) and caused pulmonary hypertension in rats. Here we show that monocytes overexpressing HERV-K dUTPase, as opposed to GFP, can release HERV-K dUTPase in extracellular vesicles (EVs) that cause pulmonary hypertension in mice in association with endothelial mesenchymal transition (EndMT) related to induction of SNAIL/SLUG and proinflammatory molecules IL-6 as well as VCAM1. In PAECs, HERV-K dUTPase requires TLR4-myeloid differentiation primary response-88 to increase IL-6 and SNAIL/SLUG, and HERV-K dUTPase interaction with melanoma cell adhesion molecule (MCAM) is necessary to upregulate VCAM1. TLR4 engagement induces p-p38 activation of NF-κB in addition to p-pSMAD3 required for SNAIL and pSTAT1 for IL-6. HERV-K dUTPase interaction with MCAM also induces p-p38 activation of NF-κB in addition to pERK1/2-activating transcription factor-2 (ATF2) to increase VCAM1. Thus in PAH, monocytes or macrophages can release HERV-K dUTPase in EVs, and HERV-K dUTPase can engage dual receptors and signaling pathways to subvert PAEC transcriptional machinery to induce EndMT and associated proinflammatory molecules.


Subject(s)
Endogenous Retroviruses , Epithelial-Mesenchymal Transition/immunology , Hypertension, Pulmonary , Macrophages/immunology , Monocytes/immunology , Pulmonary Artery , Pyrophosphatases/metabolism , Animals , CD146 Antigen/metabolism , Endogenous Retroviruses/metabolism , Endogenous Retroviruses/pathogenicity , Endothelial Cells/metabolism , Hypertension, Pulmonary/immunology , Hypertension, Pulmonary/metabolism , Hypertension, Pulmonary/virology , Inflammation/metabolism , Inflammation/virology , Mice , Pulmonary Artery/immunology , Pulmonary Artery/pathology , Signal Transduction , Snail Family Transcription Factors/metabolism
5.
Am J Respir Cell Mol Biol ; 65(4): 413-429, 2021 10.
Article in English | MEDLINE | ID: mdl-34014809

ABSTRACT

Extracellular vesicles (EVs) have emerged as important mediators in cell-cell communication; however, their relevance in pulmonary hypertension (PH) secondary to human immunodeficiency virus (HIV) infection is yet to be explored. Considering that circulating monocytes are the source of the increased number of perivascular macrophages surrounding the remodeled vessels in PH, this study aimed to identify the role of circulating small EVs and EVs released by HIV-infected human monocyte-derived macrophages in the development of PH. We report significantly higher numbers of plasma-derived EVs carrying higher levels of TGF-ß1 (transforming growth factor-ß1) in HIV-positive individuals with PH compared with individuals without PH. Importantly, levels of these TGF-ß1-loaded, plasma-derived EVs correlated with pulmonary arterial systolic pressures and CD4 counts but did not correlate with the Dl CO or viral load. Correspondingly, enhanced TGF-ß1-dependent pulmonary endothelial injury and smooth muscle hyperplasia were observed. HIV-1 infection of monocyte-derived macrophages in the presence of cocaine resulted in an increased number of TGF-ß1-high EVs, and intravenous injection of these EVs in rats led to increased right ventricle systolic pressure accompanied by myocardial injury and increased levels of serum ET-1 (endothelin-1), TNF-α, and cardiac troponin-I. Conversely, pretreatment of rats with TGF-ß receptor 1 inhibitor prevented these EV-mediated changes. Findings define the ability of macrophage-derived small EVs to cause pulmonary vascular modeling and PH via modulation of TGF-ß signaling and suggest clinical implications of circulating TGF-ß-high EVs as a potential biomarker of HIV-associated PH.


Subject(s)
HIV Infections/complications , HIV/pathogenicity , Transforming Growth Factor beta1/metabolism , Animals , Extracellular Vesicles/virology , Humans , Hypertension, Pulmonary/virology , Macrophages/virology , Male , Monocytes/virology , Pulmonary Arterial Hypertension/virology , Rats, Inbred F344 , Receptors, Transforming Growth Factor beta/metabolism , Vascular Remodeling/physiology
6.
Molecules ; 26(7)2021 Mar 29.
Article in English | MEDLINE | ID: mdl-33805419

ABSTRACT

The COVID-19 pandemic has reached over 100 million worldwide. Due to the multi-targeted nature of the virus, it is clear that drugs providing anti-COVID-19 effects need to be developed at an accelerated rate, and a combinatorial approach may stand to be more successful than a single drug therapy. Among several targets and pathways that are under investigation, the renin-angiotensin system (RAS) and specifically angiotensin-converting enzyme (ACE), and Ca2+-mediated SARS-CoV-2 cellular entry and replication are noteworthy. A combination of ACE inhibitors and calcium channel blockers (CCBs), a critical line of therapy for pulmonary hypertension, has shown therapeutic relevance in COVID-19 when investigated independently. To that end, we conducted in silico modeling using BIOiSIM, an AI-integrated mechanistic modeling platform by utilizing known preclinical in vitro and in vivo datasets to accurately simulate systemic therapy disposition and site-of-action penetration of the CCBs and ACEi compounds to tissues implicated in COVID-19 pathogenesis.


Subject(s)
Antiviral Agents/pharmacokinetics , COVID-19 Drug Treatment , Drug Repositioning/methods , Hypertension, Pulmonary/drug therapy , Angiotensin-Converting Enzyme Inhibitors/pharmacokinetics , Antiviral Agents/blood , Biosimilar Pharmaceuticals , COVID-19/complications , Calcium Channel Blockers/pharmacokinetics , Computer Simulation , Databases, Pharmaceutical , Drug Development/methods , Humans , Hypertension, Pulmonary/virology , Tissue Distribution
7.
PLoS One ; 16(2): e0243274, 2021.
Article in English | MEDLINE | ID: mdl-33621231

ABSTRACT

BACKGROUND: People living with human immunodeficiency virus (PLWH) are at risk of developing pulmonary hypertension (PH) and right ventricular (RV) dysfunction, but understanding of the relationship of RV function to afterload (RV-PA coupling) is limited. We evaluated the clinical and hemodynamic characteristics of human immunodeficiency virus (HIV)-associated PH. METHODS: We performed a retrospective review of patients with a diagnosis of HIV undergoing right heart catheterization (RHC) from 2000-2016 in a tertiary care center. Inclusion criteria were diagnosis of HIV, age ≥ 18 years and availability of RHC data. PH was classified as either pulmonary arterial hypertension (PAH; mean pulmonary arterial pressure [mPAP] ≥ 25mmHg with pulmonary artery wedge pressure [PAWP] ≤ 15mmHg) or pulmonary venous hypertension (PVH; mPAP ≥ 25mmHg with PAWP > 15). We collected demographics, CD4 cell count, HIV viral load, RHC and echocardiographic data. The single beat method was used to calculate RV-PA coupling from RHC. RESULTS: Sixty-two PLWH with a clinical likelihood for PH underwent RHC. Thirty-two (52%) met PH criteria (15 with PAH, 17 with PVH). Average time from diagnosis of HIV to diagnosis of PH was 11 years. Eleven of 15 individuals with PAH were on antiretroviral therapy (ART) while all 17 patients with PVH were on ART. Compared to PLWH without PH, those with PH had an increased likelihood of having a detectable HIV viral load and lower CD4 cell counts. PLWH with PAH or PVH had increased RV afterload with normal RV contractility, and preserved RV-PA coupling. CONCLUSION: PLWH with PH (PAH or PVH) were more likely to have a detectable HIV viral load and lower CD4 count at the time of RHC. PLWH with PAH or PVH had increased RV afterload, normal RV contractility, with preserved RV-PA coupling suggestive of an early onset, mild, and compensated form of PH. These results should be confirmed in larger studies.


Subject(s)
HIV Infections/complications , Hypertension, Pulmonary/etiology , Ventricular Dysfunction, Right/etiology , Adult , Cardiac Catheterization , Female , HIV/isolation & purification , HIV Infections/diagnosis , HIV Infections/physiopathology , HIV Infections/virology , Humans , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/physiopathology , Hypertension, Pulmonary/virology , Kaplan-Meier Estimate , Male , Middle Aged , Myocardial Contraction , Pulmonary Arterial Hypertension/diagnosis , Pulmonary Arterial Hypertension/etiology , Pulmonary Arterial Hypertension/physiopathology , Pulmonary Arterial Hypertension/virology , Retrospective Studies , Ventricular Dysfunction, Right/diagnosis , Ventricular Dysfunction, Right/physiopathology , Ventricular Dysfunction, Right/virology , Viral Load
8.
Intern Emerg Med ; 16(1): 1-5, 2021 01.
Article in English | MEDLINE | ID: mdl-32936380

ABSTRACT

In patients with the novel coronavirus (COVID-19) infection, the echocardiographic assessment of the right ventricle (RV) represents a pivotal element in the understanding of current disease status and in monitoring disease progression. The present manuscript is aimed at specifically describing the echocardiographic assessment of the right ventricle, mainly focusing on the most useful parameters and the time of examination. The RV direct involvement happens quite often due to preferential lung tropism of COVID-19 infection, which is responsible for an interstitial pneumonia characterized also by pulmonary hypoxic vasoconstriction (and thus an RV afterload increase), often evolving in acute respiratory distress syndrome (ARDS). The indirect RV involvement may be due to the systemic inflammatory activation, caused by COVID-19, which may affect the overall cardiovascular system mainly by inducing an increase in troponin values and in the sympathetic tone and altering the volemic status (mainly by affecting renal function). Echocardiographic parameters, specifically focused on RV (dimensions and function) and pulmonary circulation (systolic pulmonary arterial pressures, RV wall thickness), are to be measured in a COVID-19 patient with respiratory failure and ARDS. They have been selected on the basis of their feasibility (that is easy to be measured, even in short time) and usefulness for clinical monitoring. It is advisable to measure the same parameters in the single patient (based also on the availability of valid acoustic windows) which are identified in the first examination and repeated in the following ones, to guarantee a reliable monitoring. Information gained from a clinically-guided echocardiographic assessment holds a clinical utility in the single patients when integrated with biohumoral data (indicating systemic activation), blood gas analysis (reflecting COVID-19-induced lung damage) and data on ongoing therapies (in primis ventilatory settings).


Subject(s)
COVID-19/complications , Echocardiography , Heart Ventricles/diagnostic imaging , Ventricular Dysfunction, Right/diagnosis , Humans , Hypertension, Pulmonary/virology , Prone Position , Respiratory Distress Syndrome/virology , Stroke Volume , Tricuspid Valve/diagnostic imaging , Vena Cava, Inferior/diagnostic imaging
9.
Sci Rep ; 10(1): 18729, 2020 10 30.
Article in English | MEDLINE | ID: mdl-33127959

ABSTRACT

Hepatitis C virus (HCV) may increase pulmonary hypertension (PH) risk among people living with HIV (PLWH). Prior studies on this topic have been relatively small and examined selected populations. We determine whether HIV/HCV coinfection is associated with higher pulmonary artery systolic pressure (PASP) and prevalent echocardiographic PH. We performed a cross-sectional analysis of 6032 (16% HIV/HCV coinfected) Veterans Aging Cohort Study participants enrolled 4/1/2003-9/30/2012 with echocardiographic PASP measures. We performed multiple linear and logistic regression analyses to determine whether HIV/HCV mono- or co-infection were associated with PASP and PH compared to uninfected individuals. Individuals with HIV/HCV coinfection displayed a higher PASP than uninfected individuals ([Formula: see text]=1.10, 95% CI 0.01, 2.20) but there was no association between HIV/HCV coinfection and prevalent PH. Subset analyses examined HIV and HCV disease severity markers separately and jointly. Among PLWH, HCV coinfection ([Formula: see text]=1.47, 95% CI 0.26, 2.67) and CD4 + cell count ([Formula: see text]= - 0.68, 95% CI - 1.10, - 0.27), but not HIV viral load nor ART regimen, were associated with PASP. Among people with HCV, neither HIV coinfection nor HCV biomarkers were associated with PASP. Among US veterans referred for echocardiography, HIV/HCV coinfection was not associated with a clinically significant elevation in pulmonary pressure. Lower absolute CD4 + T-cell count was inversely associated with PASP which warrants further investigation in prospective studies.


Subject(s)
Biomarkers/metabolism , HIV/pathogenicity , Hepacivirus/pathogenicity , Hypertension, Pulmonary/virology , Aged , Blood Pressure/physiology , CD4 Lymphocyte Count , CD4-Positive T-Lymphocytes/metabolism , Cohort Studies , Coinfection/virology , Cross-Sectional Studies , Echocardiography , Female , Humans , Male , Middle Aged , Prospective Studies , Pulmonary Artery/physiology , United States , Veterans , Viral Load/physiology
11.
Hypertension ; 76(3): 651-661, 2020 09.
Article in English | MEDLINE | ID: mdl-32783758

ABSTRACT

Discovery of ACE2 (angiotensin-converting enzyme 2) revealed that the renin-angiotensin system has 2 counterbalancing arms. ACE2 is a major player in the protective arm, highly expressed in lungs and gut with the ability to mitigate cardiopulmonary diseases such as inflammatory lung disease. ACE2 also exhibits activities involving gut microbiome, nutrition, and as a chaperone stabilizing the neutral amino acid transporter, B0AT1, in gut. But the current interest in ACE2 arises because it is the cell surface receptor for the novel coronavirus, severe acute respiratory syndrome coronavirus-2, to infect host cells, similar to severe acute respiratory syndrome coronavirus-2. This suggests that ACE2 be considered harmful, however, because of its important other roles, it is paradoxically a potential therapeutic target for cardiopulmonary diseases, including coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2. This review describes the discovery of ACE2, its physiological functions, and its place in the renin-angiotensin system. It illustrates new analyses of the structure of ACE2 that provides better understanding of its actions particularly in lung and gut, shedding of ACE2 by ADAM17 (a disintegrin and metallopeptidase domain 17 protein), and role of TMPRSS2 (transmembrane serine proteases 2) in severe acute respiratory syndrome coronavirus-2 entry into host cells. Cardiopulmonary diseases are associated with decreased ACE2 activity and the mitigation by increasing ACE2 activity along with its therapeutic relevance are addressed. Finally, the potential use of ACE2 as a treatment target in COVID-19, despite its role to allow viral entry into host cells, is suggested.


Subject(s)
Coronavirus Infections , Hypertension, Pulmonary , Pandemics , Peptidyl-Dipeptidase A/physiology , Pneumonia, Viral , Angiotensin-Converting Enzyme 2 , Betacoronavirus/physiology , COVID-19 , Coronavirus Infections/metabolism , Coronavirus Infections/physiopathology , Coronavirus Infections/therapy , Disease Management , Humans , Hypertension, Pulmonary/metabolism , Hypertension, Pulmonary/virology , Pneumonia, Viral/metabolism , Pneumonia, Viral/physiopathology , Pneumonia, Viral/therapy , Renin-Angiotensin System/physiology , SARS-CoV-2
12.
Physiol Rev ; 100(2): 603-632, 2020 04 01.
Article in English | MEDLINE | ID: mdl-31600121

ABSTRACT

Despite anti-retroviral therapy (ART), human immunodeficiency virus-1 (HIV)-related pulmonary disease continues to be a major cause of morbidity and mortality for people living with HIV (PLWH). The spectrum of lung diseases has changed from acute opportunistic infections resulting in death to chronic lung diseases for those with access to ART. Chronic immune activation and suppression can result in impairment of innate immunity and progressive loss of T cell and B cell functionality with aberrant cytokine and chemokine responses systemically as well as in the lung. HIV can be detected in the lungs of PLWH and has profound effects on cellular immune functions. In addition, HIV-related lung injury and disease can occur secondary to a number of mechanisms including altered pulmonary and systemic inflammatory pathways, viral persistence in the lung, oxidative stress with additive effects of smoke exposure, microbial translocation, and alterations in the lung and gut microbiome. Although ART has had profound effects on systemic viral suppression in HIV, the impact of ART on lung immunology still needs to be fully elucidated. Understanding of the mechanisms by which HIV-related lung diseases continue to occur is critical to the development of new preventive and therapeutic strategies to improve lung health in PLWH.


Subject(s)
AIDS-Related Opportunistic Infections/immunology , Asthma/immunology , HIV Infections/immunology , HIV/immunology , Hypertension, Pulmonary/immunology , Lung Neoplasms/immunology , Lung/immunology , Pulmonary Disease, Chronic Obstructive/immunology , Respiratory Tract Infections/immunology , AIDS-Related Opportunistic Infections/drug therapy , AIDS-Related Opportunistic Infections/microbiology , AIDS-Related Opportunistic Infections/virology , Animals , Anti-HIV Agents/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Asthma/drug therapy , Asthma/virology , Disease Models, Animal , HIV/drug effects , HIV/pathogenicity , HIV Infections/drug therapy , HIV Infections/virology , Host-Pathogen Interactions , Humans , Hypertension, Pulmonary/drug therapy , Hypertension, Pulmonary/virology , Immunocompromised Host , Lung/drug effects , Lung/microbiology , Lung/virology , Lung Neoplasms/drug therapy , Lung Neoplasms/virology , Prognosis , Pulmonary Disease, Chronic Obstructive/drug therapy , Pulmonary Disease, Chronic Obstructive/virology , Respiratory Tract Infections/drug therapy , Respiratory Tract Infections/microbiology , Respiratory Tract Infections/virology , Risk Factors
13.
Am J Physiol Heart Circ Physiol ; 315(3): H581-H589, 2018 09 01.
Article in English | MEDLINE | ID: mdl-29906223

ABSTRACT

Pulmonary hypertension (PH) has been observed in up to 75% of infants with moderate to severe respiratory syncytial virus (RSV) bronchiolitis and is associated with significant morbidity and mortality in infants with congenital heart disease. The purpose of the present study was to establish a mouse model of PH secondary to RSV bronchiolitis that mimics the disease etiology as it occurs in infants. Neonatal mice were infected with RSV at 5 days of age and then reinfected 4 wk later. Serum-free medium was administered to age-matched mice as a control. Echocardiography and right ventricular systolic pressure (RVSP) measurements via right jugular vein catheterization were conducted 5 and 6 days after the second infection, respectively. Peripheral capillary oxygen saturation monitoring did not indicate hypoxia at 2-4 days post-RSV infection, before reinfection, and at 2-7 days after reinfection. RSV-infected mice had significantly higher RVSP than control mice. Pulsed-wave Doppler recording of the pulmonary blood flow by echocardiogram demonstrated a significantly shortened pulmonary artery acceleration time and decreased pulmonary artery acceleration time-to-ejection time ratio in RSV-infected mice. Morphometry showed that RSV-infected mice exhibited a significantly higher pulmonary artery medial wall thickness and had an increased number of muscularized pulmonary arteries compared with control mice. These findings, confirmed by RVSP measurements, demonstrate the development of PH in the lungs of mice infected with RSV as neonates. This animal model can be used to study the pathogenesis of PH secondary to RSV bronchiolitis and to assess the effect of treatment interventions. NEW & NOTEWORTHY This is the first mouse model of respiratory syncytial virus-induced pulmonary hypertension, to our knowledge. This model will allow us to decipher molecular mechanisms responsible for the pathogenesis of pulmonary hypertension secondary to respiratory syncytial virus bronchiolitis with the use of knockout and/or transgenic animals and to monitor therapeutic effects with echocardiography.


Subject(s)
Bronchiolitis, Viral/complications , Disease Models, Animal , Hypertension, Pulmonary/virology , Respiratory Syncytial Virus Infections/complications , Animals , Blood Pressure , Bronchiolitis, Viral/pathology , Hypertension, Pulmonary/etiology , Hypertension, Pulmonary/pathology , Mice , Mice, Inbred BALB C , Pulmonary Artery/pathology , Respiratory Syncytial Virus Infections/pathology
14.
Arch. argent. pediatr ; 116(3): 437-441, jun. 2018. tab, ilus
Article in Spanish | LILACS, BINACIS | ID: biblio-950022

ABSTRACT

La hipertensión pulmonar asociada a la infección por virus de inmunodeficiencia humana es una enfermedad sumamente infrecuente en pediatría, por lo que requiere alta sospecha clínica para llegar a su diagnóstico. Su aparición es de pronóstico desfavorable, pero el diagnóstico precoz y el tratamiento específico pueden mejorar su evolución. Se presenta el caso clínico de un paciente de 15 años con diagnóstico de infección por virus de inmunodeficiencia humana de transmisión vertical, sin tratamiento antirretroviral, con tos y disnea de esfuerzo progresiva asociadas a signos de falla cardíaca derecha en el cual se diagnosticó hipertensión pulmonar grave. Luego de descartarse otras causas, se asumió la hipertensión pulmonar asociada a la infección por virus de inmunodeficiencia humana. Se realizó el tratamiento con sildenafil y presentó buena respuesta.


Pulmonary hypertension associated with human immunodeficiency virus infection is an extremely rare disease in pediatrics; it requires a high clinical suspicion to reach a diagnosis. Its appearance poses an unfavorable prognostic, but early diagnosis and specific treatment can improve outcomes. We report the clinical case of a fifteen-year-old patient diagnosed with human immunodeficiency virus infection of vertical transmission, without antiretroviral treatment, with cough and progressive exertional dyspnea, associated with signs of right heart failure in which severe pulmonary hypertension was diagnosed. After discarding other causes, it was assumed pulmonary hypertension associated with human immunodeficiency virus infection. Treatment was performed with sildenafil with good response.


Subject(s)
Humans , Adolescent , Vasodilator Agents/therapeutic use , HIV Infections/complications , Sildenafil Citrate/therapeutic use , Hypertension, Pulmonary/drug therapy , Severity of Illness Index , HIV Infections/transmission , Treatment Outcome , Infectious Disease Transmission, Vertical , Heart Failure/diagnosis , Heart Failure/virology , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/virology
15.
Arch Argent Pediatr ; 116(3): e437-e441, 2018 06 01.
Article in Spanish | MEDLINE | ID: mdl-29756719

ABSTRACT

Pulmonary hypertension associated with human immunodeficiency virus infection is an extremely rare disease in pediatrics; it requires a high clinical suspicion to reach a diagnosis. Its appearance poses an unfavorable prognostic, but early diagnosis and specific treatment can improve outcomes. We report the clinical case of a fifteen-year-old patient diagnosed with human immunodeficiency virus infection of vertical transmission, without antiretroviral treatment, with cough and progressive exertional dyspnea, associated with signs of right heart failure in which severe pulmonary hypertension was diagnosed. After discarding other causes, it was assumed pulmonary hypertension associated with human immunodeficiency virus infection. Treatment was performed with sildenafil with good response.


La hipertensión pulmonar asociada a la infección por virus de inmunodeficiencia humana es una enfermedad sumamente infrecuente en pediatría, por lo que requiere alta sospecha clínica para llegar a su diagnóstico. Su aparición es de pronóstico desfavorable, pero el diagnóstico precoz y el tratamiento específico pueden mejorar su evolución. Se presenta el caso clínico de un paciente de 15 años con diagnóstico de infección por virus de inmunodeficiencia humana de transmisión vertical, sin tratamiento antirretroviral, con tos y disnea de esfuerzo progresiva asociadas a signos de falla cardíaca derecha en el cual se diagnosticó hipertensión pulmonar grave. Luego de descartarse otras causas, se asumió la hipertensión pulmonar asociada a la infección por virus de inmunodeficiencia humana. Se realizó el tratamiento con sildenafil y presentó buena respuesta.


Subject(s)
HIV Infections/complications , Hypertension, Pulmonary/drug therapy , Sildenafil Citrate/therapeutic use , Vasodilator Agents/therapeutic use , Adolescent , HIV Infections/transmission , Heart Failure/diagnosis , Heart Failure/virology , Humans , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/virology , Infectious Disease Transmission, Vertical , Male , Severity of Illness Index , Treatment Outcome
16.
Adv Clin Exp Med ; 26(3): 475-481, 2017.
Article in English | MEDLINE | ID: mdl-28791823

ABSTRACT

BACKGROUND: The prevalence of primitive pulmonary arterial hypertension (PAH) in patients with human immunodeficiency virus infection (HIV) is estimated at approximately 0.5%, significantly higher than in the general population. OBJECTIVES: This study aimed to assess the echocardiographic modifications in HIV-associated pulmonary arterial hypertension (PAH). MATERIAL AND METHODS: A group of 117 patients, aged under 16, with horizontally transmitted HIV staged according to the U.S. Center for Disease Control and Prevention criteria, were included in this prospective study, with echocardiographic abnormalities in 79 children. The study group consisted of 27 HIV-infected patients with PAH, while the control group consisted of 38 patients with normal ultrasound features. The diagnostic criterion for PAH was the presence of a mean pulmonary artery pressure above 25 mm Hg, determined at 2 consecutive measurements having at least 6 months distance between them. All subjects underwent a complex echocardiographic assessment, including assessment of left and right ventricular hypertrophy and evaluation of left ventricular function, associated with determination of the immunological stage. RESULTS: We recorded the presence of PAH in 27 patients (23.08%), in whom an average value of 31.48 mm Hg was recorded for pulmonary artery pressure. All patients had mild forms of PAH. Age, gender and immunological stage showed no significant differences in the PAH group compared to patients in the control group. Right ventricular hypertrophy was encountered in 95.23% and left ventricular hypertrophy in 88.88% of the patients with PAH. Left ventricular dysfunction, a complication of pulmonary hypertension, was relatively rare (11.11%). CONCLUSIONS: In children with HIV infection, PAH is present in a relatively mild form and does not correlate with the clinical and immunological stage of HIV infection, evolving as a seemingly primitive condition.


Subject(s)
HIV Infections/physiopathology , Hypertension, Pulmonary/physiopathology , Pulmonary Artery/physiopathology , Adolescent , Echocardiography/methods , Female , Humans , Hypertension, Pulmonary/virology , Longitudinal Studies , Male , Prevalence , Prospective Studies , Pulmonary Artery/virology , Stroke Volume/physiology , Ventricular Dysfunction, Left/physiopathology , Ventricular Dysfunction, Left/virology , Ventricular Function, Left/physiology
17.
Infect Disord Drug Targets ; 17(1): 43-51, 2017.
Article in English | MEDLINE | ID: mdl-27919209

ABSTRACT

BACKGROUND: Echocardiography is a reliable means for the diagnosis of functional and valvular diseases of the heart in HIV positive and HIV negative patients. The current study was to evaluate echocardiographic abnormalities in HIV positive patients under an antiretroviral therapy (ART) program in Tehran, Imam Khomeini Hospital, Iran. METHODS: This is a descriptive cross-sectional study, conducted among 231 HIV-1 positive patients under ART. All HIV positive patients including 150 men (65%) and 81 women (35%) (mean age of 41 years) were assessed by trans-thoracic echocardiography (TTE) in Imam Khomeini Hospital, over the period from 2013 to 2014. RESULTS: The mean CD4 count was 408 cell/µl, and the average left ventricular ejection fraction (LVEF) was 59.5%. There was an inverse correlation between age and LVEF level. Nevirapine users showed a significantly higher LVEF than non-users. Left ventricular systolic dysfunction (LVSD) was diagnosed in 5.6% along with the increase in age, while left ventricular diastolic dysfunction (LVDD) was reported in 19.5% of patients associated with age and smoking. Here, the mean systolic pulmonary arterial pressure (SPAP) was only 20 mmHg and just four percent of the patients suffered pulmonary hypertension. Almost 44% had a heart valve disorder among which mitral valve prolapse is the most common problem. Pericardial effusion was not found in any patients. CONCLUSION: It seems that heart disorders with no suggestive symptoms in HIV positive patients, and mainly older adults who have traditional risk factors for heart diseases, should be seriously considered by health providers.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/complications , HIV Infections/drug therapy , Heart Diseases/diagnostic imaging , Adult , Anti-HIV Agents/adverse effects , CD4 Lymphocyte Count , Cross-Sectional Studies , Echocardiography , Female , HIV Infections/virology , Heart Diseases/complications , Heart Diseases/physiopathology , Humans , Hypertension, Pulmonary/complications , Hypertension, Pulmonary/drug therapy , Hypertension, Pulmonary/virology , Iran , Male , Middle Aged , Risk Factors , Ventricular Dysfunction, Left/complications , Ventricular Dysfunction, Left/diagnostic imaging , Young Adult
19.
Autophagy ; 12(12): 2420-2438, 2016 12.
Article in English | MEDLINE | ID: mdl-27723373

ABSTRACT

Intravenous drug use is one of the major risk factors for HIV-infection in HIV-related pulmonary arterial hypertension patients. We previously demonstrated exaggerated pulmonary vascular remodeling with enhanced apoptosis followed by increased proliferation of pulmonary endothelial cells on simultaneous exposure to both opioids and HIV protein(s). Here we hypothesize that the exacerbation of autophagy may be involved in the switching of endothelial cells from an early apoptotic state to later hyper-proliferative state. Treatment of human pulmonary microvascular endothelial cells (HPMECs) with both the HIV-protein Tat and morphine resulted in an oxidative stress-dependent increase in the expression of various markers of autophagy and formation of autophagosomes when compared to either Tat or morphine monotreatments as demonstrated by western blot, transmission electron microscopy and immunofluorescence. Autophagy flux experiments suggested increased formation rather than decreased clearance of autolysosomes. Inhibition of autophagy resulted in a significant increase in apoptosis and reduction in proliferation of HPMECs with combined morphine and Tat (M+T) treatment compared to monotreatments whereas stimulation of autophagy resulted in opposite effects. Significant increases in the expression of autophagy markers as well as the number of autophagosomes and autolysosomes was observed in the lungs of SIV-infected macaques and HIV-infected humans exposed to opioids. Overall our findings indicate that morphine in combination with viral protein(s) results in the induction of autophagy in pulmonary endothelial cells that may lead to an increase in severity of angio-proliferative remodeling of the pulmonary vasculature on simian and human immunodeficiency virus infection in the presence of opioids.


Subject(s)
Apoptosis Regulatory Proteins/adverse effects , Autophagy , Endothelial Cells/pathology , HIV Infections/complications , Hypertension, Pulmonary/pathology , Lung/pathology , Morphine/adverse effects , Recombinant Fusion Proteins/adverse effects , tat Gene Products, Human Immunodeficiency Virus/adverse effects , Animals , Apoptosis/drug effects , Apoptosis/genetics , Autophagosomes/drug effects , Autophagosomes/metabolism , Autophagosomes/ultrastructure , Autophagy/drug effects , Autophagy/genetics , Biomarkers/metabolism , Cell Proliferation/drug effects , Endothelial Cells/metabolism , Endothelial Cells/ultrastructure , Endothelium, Vascular/pathology , HIV Infections/pathology , Humans , Hypertension, Pulmonary/complications , Hypertension, Pulmonary/virology , Lysosomes/drug effects , Lysosomes/metabolism , Lysosomes/ultrastructure , Macaca , Microvessels/pathology , Models, Biological , Oxidative Stress/drug effects , RNA, Messenger/genetics , RNA, Messenger/metabolism , Simian Acquired Immunodeficiency Syndrome/pathology , Simian Acquired Immunodeficiency Syndrome/virology , Simian Immunodeficiency Virus/physiology , Substance Abuse, Intravenous/complications , Substance Abuse, Intravenous/pathology , Substance Abuse, Intravenous/virology , Survivin
20.
Lung ; 194(5): 807-12, 2016 10.
Article in English | MEDLINE | ID: mdl-27344326

ABSTRACT

PURPOSE: Crimean-Congo hemorrhagic fever (CCHF) is a viral tick-borne illness. Although its etiopathogenesis is not clearly understood, it is known to be a Nairovirus. We aimed to examine the viral effects of intense systemic inflammation and vascular damage on the pulmonary vascular beds and lung tissues. METHODS: A total of 45 patients who were diagnosed with CCHF were considered for this retrospective study. In this patient group, those whose lungs had been visualized via thoracic computer tomography (CT) were entered into the study. Diameters of the pulmonary trunk, main pulmonary arteries, atria, and ventricles were measured. Study group measurements were compared with the control group, which included patients with normal thoracic CT. RESULTS: Overall, 90 patients were enrolled in the study, with 45 patients in the study group and 45 in the control group. In the study group, the man-to-woman balance was 3/2. The average age in the study group was 54.07 ± 17.91 years. In comparing the average diameters of pulmonary arteries in the study and control groups, the study group's average pulmonary artery diameter was significantly larger than the control group (p < 0.001). CONCLUSIONS: The increase in diameters of the pulmonary trunks and main pulmonary arteries due to CCHF was first shown in this current study. Moreover, due to our findings, it should be noted that with the rise in pulmonary artery diameter in CCHF, pulmonary hypertension can appear acutely, and this condition can be significantly alter clinical course and follow-up of the viral illness.


Subject(s)
Hemorrhagic Fever, Crimean/complications , Hypertension, Pulmonary/virology , Lung/diagnostic imaging , Pulmonary Artery/pathology , Acute Disease , Adult , Aged , Case-Control Studies , Female , Humans , Lung/blood supply , Male , Middle Aged , Organ Size , Pulmonary Artery/diagnostic imaging , Retrospective Studies , Tomography, X-Ray Computed , Vasculitis/complications , Vasculitis/virology
SELECTION OF CITATIONS
SEARCH DETAIL
...